Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04447943 QTc study in healthy adults
NCT02785770Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of edelinontrine in sickle cell disease (SCD) and Alzheimer's disease (AD) (4 arms), sponsored by Pfizer. Primary endpoint: Corrected QT Interval Using Fridericia's Correction Method. Started Jun 2016; status: completed.
02
Drugs
edelinontrine
03
Conditions
sickle cell disease (SCD)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02785770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02785770.